PL4108664T3 - Krystaliczna postać inhibitora jak i jej zastosowanie - Google Patents
Krystaliczna postać inhibitora jak i jej zastosowanieInfo
- Publication number
- PL4108664T3 PL4108664T3 PL21757247.8T PL21757247T PL4108664T3 PL 4108664 T3 PL4108664 T3 PL 4108664T3 PL 21757247 T PL21757247 T PL 21757247T PL 4108664 T3 PL4108664 T3 PL 4108664T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- application
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010110530 | 2020-02-21 | ||
| PCT/CN2021/077228 WO2021164786A1 (zh) | 2020-02-21 | 2021-02-22 | Jak抑制剂的晶型及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4108664T3 true PL4108664T3 (pl) | 2025-08-25 |
Family
ID=77391871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21757247.8T PL4108664T3 (pl) | 2020-02-21 | 2021-02-22 | Krystaliczna postać inhibitora jak i jej zastosowanie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12486266B2 (pl) |
| EP (1) | EP4108664B1 (pl) |
| JP (1) | JP7530432B2 (pl) |
| KR (1) | KR102931124B1 (pl) |
| CN (1) | CN115038701B (pl) |
| AU (1) | AU2021222686B2 (pl) |
| ES (1) | ES3037893T3 (pl) |
| HR (1) | HRP20250851T1 (pl) |
| HU (1) | HUE073161T2 (pl) |
| PL (1) | PL4108664T3 (pl) |
| RS (1) | RS67023B1 (pl) |
| WO (1) | WO2021164786A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022161205A1 (zh) * | 2021-01-29 | 2022-08-04 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220688A1 (en) | 2005-07-27 | 2009-09-03 | Buddy Tools, Llc | Drywall tape and joint compound dispenser |
| WO2010010187A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| EP3492468B1 (en) * | 2016-07-26 | 2022-02-23 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof |
| MX2022004474A (es) * | 2016-12-16 | 2023-08-15 | Janssen Pharmaceutica Nv | Inhibidores de moléculas pequeñas de la familia de quinasas jak. |
| CN108341814B (zh) | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
| ES2973331T3 (es) * | 2018-08-23 | 2024-06-19 | Zhuhai United Laboratories Co Ltd | Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo |
| AU2020428591B2 (en) * | 2020-02-13 | 2024-05-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
| WO2022161205A1 (zh) * | 2021-01-29 | 2022-08-04 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用 |
-
2021
- 2021-02-22 WO PCT/CN2021/077228 patent/WO2021164786A1/zh not_active Ceased
- 2021-02-22 EP EP21757247.8A patent/EP4108664B1/en active Active
- 2021-02-22 CN CN202180010731.2A patent/CN115038701B/zh active Active
- 2021-02-22 ES ES21757247T patent/ES3037893T3/es active Active
- 2021-02-22 AU AU2021222686A patent/AU2021222686B2/en active Active
- 2021-02-22 HR HRP20250851TT patent/HRP20250851T1/hr unknown
- 2021-02-22 PL PL21757247.8T patent/PL4108664T3/pl unknown
- 2021-02-22 US US17/796,613 patent/US12486266B2/en active Active
- 2021-02-22 HU HUE21757247A patent/HUE073161T2/hu unknown
- 2021-02-22 KR KR1020227032610A patent/KR102931124B1/ko active Active
- 2021-02-22 RS RS20250700A patent/RS67023B1/sr unknown
- 2021-02-22 JP JP2022549366A patent/JP7530432B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102931124B1 (ko) | 2026-02-24 |
| CA3166743A1 (en) | 2021-08-26 |
| AU2021222686A1 (en) | 2022-09-01 |
| CN115038701B (zh) | 2023-06-16 |
| HUE073161T2 (hu) | 2026-01-28 |
| EP4108664A1 (en) | 2022-12-28 |
| US12486266B2 (en) | 2025-12-02 |
| JP7530432B2 (ja) | 2024-08-07 |
| EP4108664A4 (en) | 2024-03-06 |
| RS67023B1 (sr) | 2025-08-29 |
| JP2023514291A (ja) | 2023-04-05 |
| EP4108664C0 (en) | 2025-07-09 |
| ES3037893T3 (en) | 2025-10-07 |
| CN115038701A (zh) | 2022-09-09 |
| WO2021164786A1 (zh) | 2021-08-26 |
| AU2021222686B2 (en) | 2023-06-29 |
| HRP20250851T1 (hr) | 2025-09-26 |
| KR20220157398A (ko) | 2022-11-29 |
| US20230091250A1 (en) | 2023-03-23 |
| EP4108664B1 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290106A (en) | Crystalline form of atr inhibitor and use thereof | |
| DK3932919T3 (da) | Jak-inhibitorforbindelse og anvendelse deraf | |
| DK3964510T3 (da) | Krystalform af wee1-hæmmerforbindelse og anvendelse deraf | |
| IL313123A (en) | Stat3 degraders and uses thereof | |
| EP4472967A4 (en) | Iraqi Degradation Agents and Their Uses | |
| PL3788044T3 (pl) | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania | |
| EP4125884A4 (en) | COMBINATIONS OF EIF4A INHIBITORS | |
| DK4045039T3 (da) | Hæmning af human integrin-alfa4beta7 | |
| EP4069212A4 (en) | INHIBITORS OF HIF-2ALPHA | |
| EP4495113A4 (en) | KIF18A INHIBITOR | |
| SI3972960T1 (sl) | Kristalinične oblike zaviralca btk | |
| IL277778B (en) | Bcl6 inhibitors | |
| EP4508919C0 (en) | CONFIGURATION OF MULTIPLE TIME ADVANCE VALUES | |
| EP3930709A4 (en) | Lipid prodrugs of jak inhibitors and uses thereof | |
| IL286218A (en) | Solid state forms of ripretinib | |
| EP4499068A4 (en) | Iraqi Degradation Agents and Their Uses | |
| EP4337203A4 (en) | INHIBITORS OF THE MENIN-MLL INTERACTION | |
| EP4333821A4 (en) | SARS-COV-2 INHIBITORS | |
| EP4186908C0 (en) | JAK INHIBITOR COMPOUND AND ITS USE | |
| PL3997063T3 (pl) | Zastosowanie metastabilnej odmiany krystalicznej i sposób jej wytwarzania | |
| EP4041211A4 (en) | IMPROVED TOPICAL COMPOSITION OF COLCHICINE | |
| EP4408853A4 (en) | LPXC INHIBITORS AND THEIR USES | |
| IL292755A (en) | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof | |
| EP4271679A4 (en) | AMORPHOUS FORM OF PRETOMANIDES | |
| EP4384164A4 (en) | HYPOXIA-INDUCIBLE FACTOR INHIBITORS |